Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • Equity, Diversity, and Inclusion
    • Innovations in Care Delivery
    • Without Borders
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • Equity, Diversity, and Inclusion
    • Innovations in Care Delivery
    • Without Borders
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Articles
  • Issues

User menu

  • My Alerts
  • Log in

Search

  • Advanced search
Neurology Genetics
Home
A peer-reviewed clinical and translational neurology open access journal
  • My Alerts
  • Log in
Site Logo
  • Home
  • Articles
  • Issues

Share

February 2018; 4 (1) Clinical/Scientific NotesOpen Access

Late-onset and acute presentation of Brown-Vialetto-Van Laere syndrome in a Brazilian family

Sarah Camargos, Rita Guerreiro, Jose Bras, Luis Sergio Mageste
First published January 26, 2018, DOI: https://doi.org/10.1212/NXG.0000000000000215
Sarah Camargos
From the Department of Internal Medicine (S.C., L.S.M.), School of Medicine, Federal University of Minas Gerais; Neurology Service (S.C., L.S.M.), Hospital das Clinicas, Federal University de Minas Gerais, Belo Horizonte, Brazil; Department of Molecular Neuroscience (R.G., J.B.), UCL Institute of Neurology, London, United Kingdom; and Department of Medical Sciences (R.G., J.B.), Institute of Biomedicine iBiMED, University of Aveiro, Portugal.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rita Guerreiro
From the Department of Internal Medicine (S.C., L.S.M.), School of Medicine, Federal University of Minas Gerais; Neurology Service (S.C., L.S.M.), Hospital das Clinicas, Federal University de Minas Gerais, Belo Horizonte, Brazil; Department of Molecular Neuroscience (R.G., J.B.), UCL Institute of Neurology, London, United Kingdom; and Department of Medical Sciences (R.G., J.B.), Institute of Biomedicine iBiMED, University of Aveiro, Portugal.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jose Bras
From the Department of Internal Medicine (S.C., L.S.M.), School of Medicine, Federal University of Minas Gerais; Neurology Service (S.C., L.S.M.), Hospital das Clinicas, Federal University de Minas Gerais, Belo Horizonte, Brazil; Department of Molecular Neuroscience (R.G., J.B.), UCL Institute of Neurology, London, United Kingdom; and Department of Medical Sciences (R.G., J.B.), Institute of Biomedicine iBiMED, University of Aveiro, Portugal.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luis Sergio Mageste
From the Department of Internal Medicine (S.C., L.S.M.), School of Medicine, Federal University of Minas Gerais; Neurology Service (S.C., L.S.M.), Hospital das Clinicas, Federal University de Minas Gerais, Belo Horizonte, Brazil; Department of Molecular Neuroscience (R.G., J.B.), UCL Institute of Neurology, London, United Kingdom; and Department of Medical Sciences (R.G., J.B.), Institute of Biomedicine iBiMED, University of Aveiro, Portugal.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Late-onset and acute presentation of Brown-Vialetto-Van Laere syndrome in a Brazilian family
Sarah Camargos, Rita Guerreiro, Jose Bras, Luis Sergio Mageste
Neurol Genet Feb 2018, 4 (1) e215; DOI: 10.1212/NXG.0000000000000215

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
438

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Riboflavin transporter deficiency (formerly known as Brown-Vialetto-Van Laere [BVVL] or Fazio-Londe syndrome) is a neurodegenerative disorder characterized by progressive bulbar palsy with sensorineural deafness or bulbar hereditary neuropathy.1 It is caused by mutations in the riboflavin transporter genes SLC52A2 (RFVT2) or SLC52A3 (RFVT3).2,3 It is a rare syndrome with approximately 70 cases reported worldwide, with molecular diagnoses of RFVT2 or RFVT3.1,4 We have previously described the first Brazilian family with a clinical diagnosis of BVVL.5

In this report, we extend the clinical spectrum associated with this family and describe a new mutation related to the metabolism of riboflavin.

Case report

The proband was a previously healthy woman aged 34 years, who presented with hearing and vision loss in the last 6 months (figure, A). She was disturbed by facial pain, numbness in the left hemiface, difficulty moving her tongue, dysphagia, weight loss, and bilateral foot drop.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure Family pedigree and clinical improvement with riboflavin treatment

(A) The proband is marked with an arrow. This is a family member recently studied, while subjects II.8, II.9, II.10, and III.3 were previously described in Arq Neuropsiquiatr 2007;65(1):32–35. Squares represent males, and circles represent females. Black symbols represent affected family members. The proband's mother and father were found to be heterozygous for the SLC52A3 insertion (+/−). The mutation was found in homozygosity in the proband (+/+) and her aunt. (B and C) Proband's interosseal atrophy. (D and E) Improvement in facial weakness and (F and G) tongue atrophy after initiation of 1,800 mg of riboflavin.

Examination demonstrated bilateral optic atrophy, normal ocular movements, bilateral facial paresis, atrophic tongue, and flaccid dysarthria. Reflexes were brisk except for ankle reflexes that were absent. Plantar responses were indifferent. All sensory modalities were normal. Strength was globally diminished with important distal impairment and foot drop. As dysphagia and dyspnea progressed, a feeding tube was placed and noninvasive ventilation support was initiated. At that time, she was quadriplegic and could not walk.

Electroneuromyography demonstrated cervical and acute lumbar denervation, with chronic neurogenic changes. Audiologic evaluation demonstrated neurosensorial loss.

The patient was the eldest sibling of a consanguineous marriage. She had 3 maternal aunts, also sisters from a consanguineous marriage, with a probable diagnosis of BVVL syndrome.5

The patient was started on empiric treatment with riboflavin (1,800 mg per day), and within 6 months of therapy, she could walk with a cane; the feeding tube and noninvasive ventilation were withdrawn (figure, B–G). Electroneuromyography was performed after B2 treatment and demonstrated low CMAP amplitudes and persistence of recent denervation (figure e-1, http://links.lww.com/NXG/A17).

Methods

The genetic study of the patient and both parents was conducted after written informed consent was obtained. Whole-exome sequencing (WES) was performed in the index case, and whole-genome genotyping (WGG) was used to identify large tracts of homozygosity in the trio, given the apparent autosomal recessive pattern of inheritance of the disease in the family and the presence of several loops of consanguinity. The 3 samples were genotyped at the whole-genome level using Illumina HumanOmniExpress Bead chips, and results were analyzed with GenomeStudio.

Results

By analyzing the variability identified by WES in genes previously known to cause riboflavin transporter deficiency, we identified a novel homozygous insertion in SLC52A3 (ENST00000217254(SLC52A3):c.1232_1233insCTACGCTTCCCTCCCGGCCCCGCAGGTGGCCTCGTGGGTGCTTTTCAGCGGCTGCCTCAG; p.Ser411_Tyr412insTyrAlaSerLeuProAlaProGlnValAlaSerTrpValLeuPheSerGlyCysLeuSer). The mutation was confirmed to be present in homozygosity in the index and was found in heterozygosity in both parents using Sanger sequencing. In addition, WGG revealed a large (1.5 Mb) homozygous region encompassing the SLC52A3 locus (chromosome 20: 643,919–2,146,580 Mb) that was not present in either parent. Consequently, we tested the phenotypically affected aunt (II.10), and she presented the mutation in homozygosity (figure e-2, http://links.lww.com/NXG/A18).

The mutation found is neither present in homozygosity in population databases of genetic variability (ExAC and gnomAD), nor have we identified it in our in-house sequencing data from healthy controls and other diseases (n > 6,000).

Discussion

Both SCL52A3 and SCL52A2 are riboflavin transporters. Riboflavin is a precursor of flavin mononucleotide and flavin adenine dinucleotide, which are important cofactors for energy metabolism. Since the description of these 2 genes related to riboflavin transporter deficiency, the perspective about this disease has changed significantly.2,4,6 However, the mechanisms by which the disrupted proteins lead to the disease are still to be fully understood.

Motor neuron disease, neurosensorial deafness, optic neuropathy, and the involvement of cranial nerves are common in both genotypes.4,7 Nevertheless, some phenotypic differences have been described: RFVT2 mutations present predominantly upper limb weakness and sensory ataxia; such findings are not commonly seen in patients with RFVT3 mutations.7

Here, we report a Brazilian patient with late-onset and uncharacteristic acute and severe presentation, demonstrating some phenotypic heterogeneity within a family.5 The mutation, a homozygous insertion of 60 bp in SCL52A3, has not been previously described as the cause of riboflavin transporter deficiency. So far, response to riboflavin therapy was documented in 11 patients harboring mutations in RFVT3. Of them, 9 patients demonstrated some response and 2 remained stable.4,6 Some authors argue that response tends to be better and more rapid when earlier treatment is started. Riboflavin dose reposition is unknown, and treatment, although generally efficient, is empirical. In addition, there is still no evidence to reassure that treatment would prevent the occurrence of symptoms indefinitely. Despite all this, clinicians might be aware of this potentially treatable condition and initiate riboflavin supplementation as soon as diagnosis is suspected.

Author contributions

Sarah Camargos: study concept, design, acquisition of data, and study supervision. Rita Guerreiro: study concept, design, and critical revision of the manuscript for important intellectual content. Jose Bras: analysis and interpretation of the data. Luis Sergio Mageste: analysis and interpretation of the data.

Study funding

No targeted funding reported.

Disclosure

S. Camargos has served on the scientific advisory board of Teva Pharmaceuticals and has received travel funding/speaker honoraria from Roche, Teva Pharmaceuticals, and Aché Pharmaceuticals. R. Guerreiro serves on the editorial boards of Science Matters, the American Journal of Neurodegenerative Disease, and the Journal of Parkinson's Disease and has received research support from Alzheimer's Research UK and Alzheimer's Society. J. Bras serves on the editorial board of the Journal of Parkinson's Disease and has received research support from Alzheimer's Society. L.S. Mageste reports no disclosures. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/NG.

Acknowledgment

The authors acknowledge the patients who participated in this study.

Footnotes

  • Funding information and disclosures are provided at the end of the article. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/NG.

  • The Article Processing Charge was funded by the authors.

  • Received July 19, 2017.
  • Accepted in final form November 17, 2017.
  • Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

References

  1. 1.↵
    1. Bosch AM,
    2. Stroek K,
    3. Abeling NG,
    4. Waterham HR,
    5. Ijlst L,
    6. Wanders RJ
    . The Brown-Vialetto-Van Laere and Fazio Londe syndrome revisited: natural history, genetics, treatment and future perspectives. Orphanet J Rare Dis 2012;7:83.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Green P,
    2. Wiseman M,
    3. Crow YJ, et al
    . Brown-Vialetto-Van Laere syndrome, a ponto-bulbar palsy with deafness, is caused by mutations in c20orf54. Am J Hum Genet 2010;86:485–489.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Johnson JO,
    2. Gibbs JR,
    3. Megarbane A, et al
    . Exome sequencing reveals riboflavin transporter mutations as a cause of motor neuron disease. Brain 2012;135:2875–2882.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Jaeger B,
    2. Bosch AM
    . Clinical presentation and outcome of riboflavin transporter deficiency: mini review after five years of experience. J Inherit Metab Dis 2016;39:559–564.
    OpenUrlPubMed
  5. 5.↵
    1. Malheiros JA,
    2. Camargos ST,
    3. Oliveira JT,
    4. Cardoso FE
    . A Brazilian family with Brown-Vialetto-Van Laere syndrome with autosomal recessive inheritance. Arq Neuropsiquiatr 2007;65:32–35.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Bashford JA,
    2. Chowdhury FA,
    3. Shaw CE
    . Remarkable motor recovery after riboflavin therapy in adult-onset Brown-Vialetto-Van Laere syndrome. Pract Neurol 2017;17:53–56.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Foley AR,
    2. Menezes MP,
    3. Pandraud A, et al
    . Treatable childhood neuronopathy caused by mutations in riboflavin transporter RFVT2. Brain 2014;137:44–56.
    OpenUrlCrossRefPubMed
View Abstract

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.ng.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Letters

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Letters Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Case report
    • Methods
    • Results
    • Discussion
    • Author contributions
    • Study funding
    • Disclosure
    • Acknowledgment
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures

Related Articles

  • No related articles found.

Topics Discussed

  • Peripheral neuropathy

Alert Me

  • Alert me when eletters are published
Advertisement
Neurology Genetics: 7 (2)

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Genetics | Online ISSN: 2376-7839

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise